PTAFR and epilepsy: As a novel PAFR antagonist, LAU-0901 has been previously shown to be neuroprotective in inflammation, epilepsy, and ischemic stroke models (Bazan et al., 1994; Bazan, 2005; Belayev et al., 2008, 2009, 2012; Musto et al., 2016).